Business Wire

Ola Announces Futurefoundry

Share

Ola Electric, India’s leading manufacturer of EVs, today announced Ola Futurefoundry, its global center for advanced engineering and vehicle design. This center will be based in Coventry, UK, a global hub for the best automotive design and engineering talent in the world.

Ola Futurefoundry will work in-synch with the design and engineering teams based at Ola Campus in Bangalore, India. It will house global talent across multiple disciplines of 2W and 4W vehicle design, advanced high performance automotive engineering, digital & physical modeling and more. It will also house talent that will focus on vehicle R&D around new energy systems including cell technologies.

Ola will invest £100M over the next 5 years into the state of the art center and staff it with over 200 designers and automotive engineers. The centre will also partner with world class education and research institutions in the UK to collaborate on technology research and development.

Bhavish Aggarwal, Founder & CEO, Ola said, “At Ola we are building the future of mobility and continue to attract the best global talent across disciplines. Ola Futurefoundry will enable us to tap into the fantastic automotive design & engineering talent in the UK to create the next generation of electric vehicles. Futurefoundry will work in close collaboration with our headquarters in Bangalore, India to help us build the future of mobility as we make EVs affordable across the world.”

“We want to create a world class design and R&D team with global sensibilities. Ola Futurefoundry is an important step in building a multi-disciplinary team that is agile, flexible, and responsive to the various needs of our consumers around the world. We are setting up in Coventry a global epicenter of automotive and technology talent. Futurefoundry will supplement and collaborate with our core team in Bangalore, India to deliver exciting new EVs across two wheeler, 4 wheeler and other form factors.” said Wayne Burgess, Vice President of Vehicle Design, Ola Electric.

About Ola
Ola is India’s largest mobility platform. Ola revolutionised urban mobility by making it available on demand for over a billion people across 3 continents. Today, Ola continues to move the world to sustainable mobility through its ride hailing platform as well as through advanced electric vehicles manufactured at its Futurefactory, the largest, most advanced and sustainable two wheeler factory in the world. Ola also operates its new vehicle commerce platform with Ola Cars bringing seamless, digital buying, selling and ownership of vehicles to consumers. Ola is dedicated to transitioning the world to sustainable mobility and making the world better than how we found it.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Krishnakoli Dutta
Corporate Communications, Ola Electric
krishnakoli.dutta@olaelectric.com
+91 9810502191

Alastair Elwen/ Jenny Bahr
Finsbury Glover Hering
Ola-LON@finsbury.com
020 7251 3801

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting27.5.2022 15:00:00 CEST | Press release

LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number:e16102 Abstract Title:Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1]. Approximately 50% of the advanced GC patients will develop p

FEELM unveils the world's first ceramic coil disposable pod solution at Vaper Expo UK 202227.5.2022 13:38:00 CEST | Press release

FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/ (Photo: Business Wire) As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disp

Mavenir’s Containerized Open vRAN Small Cell Solution Wins Award for Outstanding Contribution to Emerging Technology or Architecture27.5.2022 09:00:00 CEST | Press release

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced to have won the SCF Small Cell Awards 2022 for Outstanding Contribution to Emerging Technology or Architecture, for its design and delivery of the first fully containerized small cell Open Virtualized Radio Access Network (Open vRAN), for indoor and outdoor connectivity. Mavenir’s containerized Open vRAN solution is a first of its kind and combines the interoperability of Open RAN with the portability and flexibility of containers. This small cell solution brings the same future-forward approaches of Open RAN and containerization having significant impacts in macro networks to small cell networks. The deployment of a containerized solution is a significant milestone in the evolution of connectivity, moving away from the physical infrastructure to a digital cloud-based environment. Containers take virtualizati

TYAN Brings Modern HPC Server Platforms for Data Centers at ISC 202227.5.2022 09:00:00 CEST | Press release

TYAN®, an industry-leading server platform design manufacturer and MiTAC Computing Technology Corporation subsidiary, will exhibit its latest HPC platforms powered by 3rd Gen AMD EPYC™ Processors with AMD 3D V-Cache™ technology for data centers deployments at the ISC 2022 event from May 30th to June 1st at booth #D400. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005002/en/ TYAN’s Server Platforms Powered by AMD EPYC 7003 Series Processors Provide the Best Foundation for Data Centers that Can be Tailored to Specific Workloads (Photo: Business Wire) “The amount of data generated by humans and machines has increased exponentially and this requires a steady increase of data center compute performance, therefore, modern data centers need balanced hardware to efficiently manage growing data volumes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “TYAN’s ser

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom